<DOC>
	<DOCNO>NCT00368953</DOCNO>
	<brief_summary>Revascularisation procedure percutaneous coronary intervention associate overall bad outcome patient diabetes mellitus . Implantation coronary stent associate high restenosis rate compare non-diabetic individual . There limited data available efficacy safety novel Yukon Choice drug-eluting stent system specifically patient diabetes mellitus . The trial determine efficacy safety novel Yukon Choice stent system compare well establish Taxus Liberté stent system . The primary endpoint `` in-stent late lumen loss '' 9 month determine invasive angiography .</brief_summary>
	<brief_title>YUKON Choice Versus TAXUS Liberté Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>age &gt; 18 year diabetes mellitus symptom ( stable unstable angina pectoris ) objective evidence myocardial ischemia one de novo lesion 1 , 2 3 native coronary artery clinically significant diameter stenosis ( 5099 % accord visual assessment operator ) lesion must cover stent length 24 mm stent diameter 3,5 mm vessel diameter 4 mm vessel area adjacent stenosis inform consent unprotected leave main disease complete occlusion target vessel instentrestenosis stenosis bypass grafts indication bypass surgery bifurcation lesion ( side branch &gt; 2,0 mm ) thrombus target lesion visualize angiography allergy contraindication concomitant medication ( clopidogrel , aspirin , heparin , contrast medium ) acute myocardial infarction within precede 48h participation another trial pregnancy severe disorder coagulation platelet function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>